Dichloroisocyanurate sodium

Cat. No.: HY-B2180: Data Sheet
SDS
Handling Instructions
FAQs
Technical Support

Dichloroisocyanurate sodium is a synthetic organochlorine compound belonging to triazine derivatives, and is commonly used as a disinfectant and biocide. Dichloroisocyanurate sodium can release hypochlorous acid to inactivate waterborne bacteria, viruses, helminths and protozoa, and can act as a hypochlorous acid reservoir to provide sustained biocidal protection.

For research use only. We do not sell to patients.

Dichloroisocyanurate sodium Chemical Structure

CAS No. : 2893-78-9

Size	Stock	Quantity
100 g	In-stock	Estimated Time of Arrival: December 31
500 g	In-stock	Estimated Time of Arrival: December 31
1 kg	In-stock	Estimated Time of Arrival: December 31

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

In Vitro

Sodium dichloroisocyanurate exhibits excellent antimicrobial activity against a variety of Gram-positive bacteria, Gram-negative bacteria and fungi, and its activity is not affected by temperature or pH^[1].
Sodium dichloroisocyanurate exhibits excellent disinfection activity against various microorganisms on fresh vegetables^[1].
Sodium dichloroisocyanurate (30 min) eliminates all coliforms and E. coli from low-turbidity water, and reduces the viable count in raw river water by 1.8-2.8 log units^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Dichloroisocyanurate sodium (0.4-10.0 mg/m³; whole-body inhalation; 6 hours/day, 7 days/week; 90 days) causes concentration-dependent pulmonary and systemic effects in Sprague-Dawley/Crl:CD rats, with a no observed adverse effect concentration (NOAEC) of 2.0 mg/m³ for both sexes^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Sprague-Dawley/Crl:CD (7 weeks old after 6 days of acclimatization; 10 males/females per exposure group, 5 males/females per recovery group)^[2]
Dosage:	0.4 mg/m³; 2.0 mg/m³; 10.0 mg/m³
Administration:	whole-body inhalation; 6 hours/day, 7 days/week; 90 days; 14-day recovery (10.0 mg/m³ group only)
Result:	Exhibited signs of lung inflammation, eosinophilic granules observed in the nasal cavity, hyperplasia of mucous cells, atrophy/degeneration of the tracheal epithelium, and thickening of the walls of the alveolar ducts in high dose group.

Molecular Weight

220.95

Formula

C₃HCl₂N₃NaO₃

CAS No.

2893-78-9

Appearance

Solid

SMILES

[Na].O=C1NC(=O)N(Cl)C(=O)N1Cl

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Store at room temperature, keep dry and cool

In solvent	-80°C	1 year
	-20°C	6 months

Purity & Documentation

Data Sheet (273 KB) SDS (252 KB) Handling Instructions (2659 KB)

References

[1]. Clasen T, et al. Sodium dichloroisocyanurate (NaDCC) tablets as an alternative to sodium hypochlorite for the routine treatment of drinking water at the household level. Int J Hyg Environ Health. 2006;209(2):173-181. [Content Brief]

[2]. Park CM, et al. Sodium dichloroisocyanurate toxicity in rats during a 90-day inhalation toxicity study. Toxicol Appl Pharmacol. 2022;456:116279. [Content Brief]